CanSino Biologics (HKG:6185) recorded a net profit attributable to shareholders of 3.0 million yuan for the third quarter of 2024 while the Earnings per share stood at 0.01 yuan for the reporting period, a Tuesday filing with the Hong Kong Exchange said.
The vaccine company's operating revenue for the three months ended Sept. 30 was 263.6 million yuan, 76.09% higher than a year ago.
The company's shares were down nearly 2% on Tuesday's close.
Price (HKD): $26.20, Change: $-0.45, Percent Change: -1.69%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。